Frazor Titus Edmondson III
Net Worth
Last updated:
What is Frazor Titus Edmondson III net worth?
The estimated net worth of Mr. Frazor Titus Edmondson III is at least $4,017,610 as of 26 Jun 2024. He owns shares worth $922,380 as insider, has earned $973,330 from insider trading and has received compensation worth at least $2,121,900 in Zai Lab Limited.
What is the salary of Frazor Titus Edmondson III?
Mr. Frazor Titus Edmondson III salary is $707,300 per year as Chief Legal Officer & Corporation Sec. in Zai Lab Limited.
How old is Frazor Titus Edmondson III?
Mr. Frazor Titus Edmondson III is 59 years old, born in 1966.
What stocks does Frazor Titus Edmondson III currently own?
As insider, Mr. Frazor Titus Edmondson III owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Zai Lab Limited (ZLAB) | Chief Legal Officer & Corporation Sec. | 25,946 | $35.55 | $922,380 |
What does Zai Lab Limited do?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Frazor Titus Edmondson III insider trading
Zai Lab Limited
Mr. Frazor Titus Edmondson III has made 8 insider trades between 2022-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,062 units of ZLAB stock worth $90,615 on 26 Jun 2024.
The largest trade he's ever made was exercising 17,548 units of ZLAB stock on 1 Jan 2024. As of 26 Jun 2024 he still owns at least 25,946 units of ZLAB stock.
Zai Lab Limited key executives
Zai Lab Limited executives and other stock owners filed with the SEC:
- Dr. Alan Bart Sandler M.D. (68) Pres & Head of Global Devel. in Oncology
- Dr. Ying Du (59) Founder, Chairperson & Chief Executive Officer
- Mr. Frazor Titus Edmondson III (59) Chief Legal Officer & Corporation Sec.
- Mr. Ki Chul Cho (47) Chief Financial Officer
- Mr. Tao Fu (53) Chief Strategy Officer